Dr. Stiening is a business development executive with a PhD in life sciences and career focus on technology commercialization. He has studied and worked in the life sciences arena for over 15 years, including academic, large industry and start-up experience. His passion for the "business of science" was realized during his first internship with Monsanto, and evidenced by dual degrees in biology and finance.

Dr. Olson was co-founder and CSO of Potentia Pharmaceuticals, which developed the world's first complement inhibitor to treat age-related macular degeneration. The drug was acquired in late 2009 by Alcon and is currently in Phase II clinicals. Prior to his start-up experiences, he held research positions at Harvard and Merck. He's worked closely with several world-renowned thought leaders in immunology, gene delivery and ophthalmology.